These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27650511)

  • 41. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
    Polak J; Hajkova H; Haskovec C; Cechova H; Marinov I; Mikulenkova D; Markova J; Markova M; Vitek A; Valkova V
    Neoplasma; 2013; 60(1):74-82. PubMed ID: 23067220
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical analysis of acute myeloid leukemia with CBFB-MYH11-positive].
    Cao TT; Zhou MH; Yuan L; Wang Q; Dou LP; Xu YY; Wang N; Wang LL; Yu L; Jing Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):305-10. PubMed ID: 23628021
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation.
    Oran B; de Lima M
    Curr Opin Hematol; 2011 Nov; 18(6):388-94. PubMed ID: 21897227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.
    Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L
    PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute myeloid leukaemia (FAB AML-M4Eo) with cryptic insertion of cbfb resulting in cbfb-Myh11 fusion.
    Douet-Guilbert N; Chauveau A; Gueganic N; Guillerm G; Tous C; Le Bris MJ; Basinko A; Morel F; Ugo V; De Braekeleer M
    Hematol Oncol; 2017 Sep; 35(3):385-389. PubMed ID: 28906004
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation.
    Hemmati PG; Vuong LG; Terwey TH; Jehn CF; le Coutre P; Penack O; Na IK; Dörken B; Arnold R
    Eur J Haematol; 2017 Feb; 98(2):160-168. PubMed ID: 27706846
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.
    Puckrin R; Atenafu EG; Claudio JO; Chan S; Gupta V; Maze D; McNamara C; Murphy T; Shuh AC; Yee K; Sibai H; Minden MD; Wei C; Stockley T; Kamel-Reid S; Schimmer AD
    Haematologica; 2021 Jan; 106(1):56-63. PubMed ID: 31896684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combining flow cytometry and
    Guolo F; Minetto P; Clavio M; Miglino M; Galaverna F; Raiola AM; Di Grazia C; Colombo N; Pozzi S; Ibatici A; Bagnasco S; Guardo D; Kunkl A; Ballerini F; Ghiggi C; Lemoli RM; Gobbi M; Bacigalupo A
    Haematologica; 2017 Sep; 102(9):e348-e351. PubMed ID: 28495917
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia.
    Miyazaki T; Fujita H; Fujimaki K; Hosoyama T; Watanabe R; Tachibana T; Fujita A; Matsumoto K; Tanaka M; Koharazawa H; Taguchi J; Tomita N; Sakai R; Fujisawa S; Kanamori H; Ishigatsubo Y
    Leuk Res; 2012 Aug; 36(8):998-1003. PubMed ID: 22551655
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute myeloid leukaemia with associated eosinophilia: justification for FIP1L1-PDGFRA screening in cases lacking the CBFB-MYH11 fusion gene.
    Sorour Y; Dalley CD; Snowden JA; Cross NC; Reilly JT
    Br J Haematol; 2009 Jul; 146(2):225-7. PubMed ID: 19466970
    [No Abstract]   [Full Text] [Related]  

  • 53. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Dominietto A
    Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [C-kit mutation in acute myeloid leukemia patients with AML1-ETO fusion gene and its clinical significance].
    Geng SX; Du X; Weng JY; Huang X; Lu ZS; Zhong LY; Guo R; Wu SJ; Wu P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):839-42. PubMed ID: 23998570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Relationship between RAD51-g135C and XRCC3-C241T polymorphisms and prognosis of inv (16)/ t(16;16) (CBFbeta-MYH11) acute myeloid leukemia].
    Liu L; Yang L; Mi YC; Li JY; Qin TJ; Xu ZF; Zhang Y; Wang JX; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):433-8. PubMed ID: 22213860
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
    Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
    Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.
    Jentzsch M; Grimm J; Bill M; Brauer D; Backhaus D; Pointner R; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
    Am J Hematol; 2021 Jul; 96(7):E237-E239. PubMed ID: 33811773
    [No Abstract]   [Full Text] [Related]  

  • 60. Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
    Duléry R; Nibourel O; Gauthier J; Elsermans V; Behal H; Coiteux V; Magro L; Renneville A; Marceau A; Boyer T; Quesnel B; Preudhomme C; Duhamel A; Yakoub-Agha I
    Bone Marrow Transplant; 2017 Apr; 52(4):539-543. PubMed ID: 28067876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.